The specific objectives of this project are to design and synthesize the following: l Congeners of lead compounds having confirmed activity, to enhance activity or potency. 2. Prodrugs with structural modifications that may provide improved pharmacokinetics, altered drug transport, improved bio-availability through increased water solubility, or increased chemical stability. 3. Other altered structures that possess elements- of both congener and prodrug. Modifications of a lead may also include partial structures. 4. Compounds related to natural products, e.g., such as alkaloids, heterocycles, nucleosides, peptides.
| Kimball, F Scott; Turunen, Brandon J; Ellis, Keith C et al. (2008) Enantiospecific synthesis and cytotoxicity of 7-(4-methoxyphenyl)-6-phenyl-2,3,8,8a-tetrahydroindolizin-5(1H)-one enantiomers. Bioorg Med Chem 16:4367-77 |
| Scott Kimball, F; Himes, Richard H; Georg, Gunda I (2008) Synthesis and evaluation of heteroaromatic 6,7-diaryl-2,3,8,8a-tetrahydroindolizin-5(1H)-ones for cytotoxicity against the HCT-116 colon cancer cell line. Bioorg Med Chem Lett 18:3248-50 |
| Kimball, F Scott; Tunoori, Ashok Rao; Victory, Samuel F et al. (2007) Synthesis, in vitro and in vivo cytotoxicity of 6,7-diaryl-2,3,8,8a-tetrahydroindolizin-5(1H)-ones. Bioorg Med Chem Lett 17:4703-7 |
| Yang, KyoungLang; Blackman, Burchelle; Diederich, Wibke et al. (2003) Formal total synthesis of (+)-salicylihalamides A and B: a combined chiral pool and RCM strategy. J Org Chem 68:10030-9 |
